Lupus Research Alliance News
Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] READ MORE

Thank You for Making a Difference During Lupus Awareness Month

June 1, 2023 What a month May was!  As we reflect upon Lupus Awareness month, the community continues to inspire.  We celebrate how ManyOne Can make a difference, and we salute all the accomplishments of those that ARE making a difference every day. Thank you for your dedication and support! Together, the community has: Advanced […] READ MORE

EULAR Presentation Showed Upadacitinib Improved Lupus Disease Activity

May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of Associations for Rheumatology of Phase 2 data presented showing that upadacitinib improved SLE disease activity and time to first flare while lowering the need for steroids. Side effects were consistent with the known safety profile.  Discovered and […] READ MORE

Lupus Research Alliance and its Clinical Research Affiliate Lupus Therapeutics Launch the Lupus Landmark Study to Accelerate Personalized Treatments in Lupus

The Lupus Landmark Study, the largest prospective observational study in lupus, will enroll 3,500 patients throughout North America over five years The Lupus Landmark Study is a key component of the Lupus Nexus, a first-of–its-kind in lupus registry, biorepository and data/knowledge portal NEW YORK, NY. May 23, 2023 – The Lupus Research Alliance and its clinical […] READ MORE

Overview of Lupus ABC Inaugural Meeting April 16-17, 2023

The Lupus Research Alliance is pleased to report that the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) held its inaugural meeting on April 16-17 in Bethesda, Maryland.  Lupus ABC is the first public-private partnership with the U.S. Food and Drug Administration (FDA) to focus specifically on advancing the development of safer and more effective treatments urgently […] READ MORE

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] READ MORE

ManyOne ARE Making the Difference

May 1, 2023 Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer opportunities to get involved in our efforts to transform lives of people with lupus. This Lupus Awareness Month, we celebrate the great successes that are already being achieved and exciting ventures coming up that involve […] READ MORE

Ten Tips During Stress Awareness Month and Beyond

April, 2023 Tips to Lower Stress During Stress Awareness Month and Beyond If you are a person with lupus and often feel stress, you’re not alone! Research has shown stress is common among people dealing with a chronic condition like lupus and can cause symptoms like depression, fatigue, and disease flares. In recognition of Stress […] READ MORE

Lupus Research Alliance Announces Four New Recipients of the Lupus Mechanisms and Targets Award

Winning projects will explore new potential treatment approaches to prevent lupus from developing or prevent or slow disease progression. New York, NY, April 20, 2023. The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing […] READ MORE

Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership

Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs  Washington, DC, March 29, 2023 – The Lupus Research Alliance (LRA) today announced the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. Food and Drug Administration (FDA), […] READ MORE

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates